ARCH Venture Partners targets $3 billion raise for latest fund

ARCH Venture Partners is targeting $3B for its 14th fund, per an SEC filing, matching the size of the fund it disclosed in 2024. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…

Kyle LaHucik · 2026-09-01

ARCH Venture Partners, one of highest-profile names in biotech investing, has outlined plans for another $3 billion fund. The new fund — its 14th — would be one of the largest batches of venture capital raised in ...

Source: Endpoints News